Hepatitis C virus (HCV) is a leading cause of chronic liver disease, and efforts to develop therapeutic vaccine strategies have been limited by immune escape due to HCV variants that are resistant to current vaccines or HCV variants that rapidly acquire new resistance-conferring mutations. Recently, the crystal structure of the viral envelope protein E2 region was resolved as well as how E2 docks to the host CD81 protein; therefore, antibodies that block this interaction should prevent viral entry into host cells. In this issue of the
Jay K. Kolls, Gyongyi Szabo
Title and authors | Publication | Year |
---|---|---|
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability
TT Spear, TP Riley, GE Lyons, GG Callender, JJ Roszkowski, Y Wang, PE Simms, GM Scurti, KC Foley, DC Murray, LM Hellman, RH McMahan, M Iwashima, E Garrett-Mayer, HR Rosen, BM Baker, MI Nishimura |
Journal of leukocyte biology | 2016 |
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors
TT Spear, GG Callender, JJ Roszkowski, KM Moxley, PE Simms, KC Foley, DC Murray, GM Scurti, M Li, JT Thomas, A Langerman, E Garrett-Mayer, Y Zhang, MI Nishimura |
Cancer Immunology, Immunotherapy | 2016 |
RNA Viruses and RNAi: Quasispecies Implications for Viral Escape
J Presloid, I Novella |
Viruses | 2015 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |